Complement inhibitors under advanced clinical development in hematologic diseases
Agent . | Target . | Disease . | Phase of development . |
---|---|---|---|
Crovalimab | C5 | PNH | 3 |
Danicopan | Factor D | PNH | 3 |
ACH-5528/ALXN-2050 | Factor D | PNH | 2 |
BCX9930 | Factor D | PNH | 2 |
Iptacopan | Factor B | PNH | 3 |
Sutimlimab | C1s | CAD | 3 |
Pegcetacoplan | C3 | AIHA PNH | 2 Early-access program |
Narsoplimab | MASP-2 | TA-TMA | Expanded-access program |
Ravulizumab | C5 | TA-TMA | 3 |
Coversin | C5 and LTB4 inhibition | TA-TMA | 3 |
Agent . | Target . | Disease . | Phase of development . |
---|---|---|---|
Crovalimab | C5 | PNH | 3 |
Danicopan | Factor D | PNH | 3 |
ACH-5528/ALXN-2050 | Factor D | PNH | 2 |
BCX9930 | Factor D | PNH | 2 |
Iptacopan | Factor B | PNH | 3 |
Sutimlimab | C1s | CAD | 3 |
Pegcetacoplan | C3 | AIHA PNH | 2 Early-access program |
Narsoplimab | MASP-2 | TA-TMA | Expanded-access program |
Ravulizumab | C5 | TA-TMA | 3 |
Coversin | C5 and LTB4 inhibition | TA-TMA | 3 |
AIHA, autoimmune hemolytic anemia; LTB4, leukotriene B4.